Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)
Close on Nov 17, 2026Market cap $16.99MP/E –Yield –
Aligos Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aligos Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$78.99M. For fiscal 2025 it was -$87.99M. The highest annual figure on record is -$54.04M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$87.99M | – |
| FY2024 | Dec 31, 2024 | -$89.15M | – |
| FY2023 | Dec 31, 2023 | -$88.13M | – |
| FY2022 | Dec 31, 2022 | -$97.58M | – |
| FY2021 | Dec 31, 2021 | -$128.32M | – |
| FY2020 | Dec 31, 2020 | -$97.83M | – |
| FY2019 | Dec 31, 2019 | -$54.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.81M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.41M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.56M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.95M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.72M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.50M | – |
See a number that looks wrong?